This grant is for the purpose of supporting the late-stage engineering and preclinical development of innovative biological products designed to safely and specifically kill HIV-infected cells. This funding opportunity aims to advance promising therapeutic agents towards clinical application by refining their design and conducting essential preclinical validation. Products of particular interest include broadly neutralizing antibodies (bNAbs), their derivatives, and other soluble, antibody-like molecules. The ultimate goal is to develop highly effective preclinical candidates that demonstrate precision in targeting and eliminating HIV-infected cells, thereby accelerating the pipeline of novel therapies to combat HIV infection and its persistence in the body.
Opportunity ID: 350713
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-AI-23-060 |
| Funding Opportunity Title: | Engineering and Preclinical Development of Biological Products that Eliminate HIV-infected Cells (UG3/UH3 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.855 — Allergy and Infectious Diseases Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Oct 25, 2023 |
| Last Updated Date: | Oct 25, 2023 |
| Original Closing Date for Applications: | Mar 13, 2024 |
| Current Closing Date for Applications: | Mar 13, 2024 |
| Archive Date: | Apr 18, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $500,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal organizations (other than Federally recognized tribal governments) Small businesses For profit organizations other than small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Independent school districts Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities State governments Public and State controlled institutions of higher education County governments City or township governments Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this Notice of Funding Opportunity (NOFO) is to support the late-stage engineering and preclinical development of innovative biological products that safely and specifically kill HIV-infected cells. Products of interest include but are not limited to broadly neutralizing antibodies (bNAbs), their derivatives, and other soluble, antibody-like molecules. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-060.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 350713 Full Announcement-RFA-AI-23-060 -> RFA-AI-23-060-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00283596 | Feb 13, 2024 | Mar 13, 2024 | View |
Package 1
Mandatory forms
350713 RR_SF424_5_0-5.0.pdf
350713 PHS398_CoverPageSupplement_5_0-5.0.pdf
350713 RR_OtherProjectInfo_1_4-1.4.pdf
350713 PerformanceSite_4_0-4.0.pdf
350713 RR_KeyPersonExpanded_4_0-4.0.pdf
350713 RR_Budget10_3_0-3.0.pdf
350713 PHS398_ResearchPlan_5_0-5.0.pdf
350713 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
350713 RR_SubawardBudget10_30_3_0-3.0.pdf
350713 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
